US Capital Global Partners, LLC

Patented OTF delivery system for ED compounds (sildenafil, tadalafil, avanafil, vardenafil) targeting a $5B+ global category. $750M equity raise mandated to US Capital Global Partners. Lead market: India (328M addressable men).

A patented Oral Thin Film (OTF) delivery system positioned to disrupt the global men's health category by delivering existing generic and branded compounds faster (15-min peak plasma vs 90 min for capsules), at lower doses, with fewer side-effects. The platform is API-agnostic, covering sildenafil, tadalafil, avanafil and vardenafil. The patent (US 63/518,795) protects polymer chemistry, mucoadhesive structure and delivery mechanism. Lead market is India (328M conservative addressable men, 37.5–48.8% ED prevalence), with expansion planned across Southeast Asia, GCC, Latin America and Sub-Saharan Africa. Consumer brand HARD TIMES™ targets emerging-market scale with a discreet, water-free format.

• US Patent 63/518,795 protecting polymer chemistry, mucoadhesive structure and OTF delivery mechanism
• $750M equity raise mandated to US Capital Global Partners (August 2024, signed by COO & Managing Partner Charles Towle)
• OTF format achieves peak plasma concentration in 15 minutes vs 30 min (tablet) and 90 min (capsule) — peer-reviewed sources: Pharmaceutical Research (2016), Drug Delivery (2018)
• API-agnostic platform compatible with sildenafil, tadalafil, avanafil and vardenafil — covers entire global prescription ED category
• Lead market India: 882M adult males, 328.9M conservatively addressable, ED prevalence 37.5–48.8% per clinical studies
• Consumer brand HARD TIMES™ developed with multiple flavour formulations; no water required for ingestion
• Advisor US Capital Global Partners has originated $25B+ in middle-market debt and equity since 1998
• Expansion roadmap covers Southeast Asia, GCC, Latin America and Sub-Saharan Africa